Towards personalized treatments for the present and next generation


The aim of the hDMT is:

  1. To develop innovative 3D human organ and disease models on chips that recapitulate healthy and diseased human tissue.
  2. To enable valorization and stimulate implementation of these models as test systems for different purposes


The main implementation in the development process of novel therapies, will be in drug testing in the latest preclinical stage before starting clinical trials, in the format of a “clinical trial on a chip”. This means that for a specific organ or disease model a number of chips will be available, each including a patient-derived organ/disease model derived from iPS cells isolated from a specific patient. In this way the real patient population is adequately represented in an in vitro form as “patients on a chip”.  This will be done in a low throughput format. Using such an approach a blood-based diagnostic test can simultaneously be developed to predict whether a specific patient is likely to respond to the drug. Importantly, while patients can only “be used” once in a clinical trial, these in vitro “patients” can in principle be generated as often as needed.


The scope of the organ and disease models on chips is: 

The models are applicable to a wide range of human-specific diseases, with genetic and/or immunological compounds, leading to personalized medicine.